Aug. 14 at 1:37 PM
$150 million is going behind the next stage of schizophrenia drug development.
MapLight Therapeutics (
$MPLT) raised
$150M following positive Phase 2 results for ML-007C-MA, including a signal in cognition.
Across the field, companies are targeting different gaps in schizophrenia care: longer-acting treatments at
$TEVA, a newly approved option from
$VNDA, and negative symptoms at
$NERV.
The pipeline is moving beyond controlling psychosis toward addressing more of the disease’s full burden.
https://
prismmarketview.com/maplight-raise
s-150-million-as-schizophrenia-drug-development-broadens/
$MPLT $TEVA $VNDA $NERV
